ERVW-1 and HIV infectious disease: We, as part of the Collaboration for AIDS Vaccine Discovery (CAVD), have been evaluating different nucleic acid vaccines, non-replicating viral vectors and Env protein components in mixed modality vaccine regimens to define best-in-class strategies to accelerate and potentiate HIV-1-specific immune responses that could help in the control of HIV infection.